Want to see GB:AZN full AI Analyst Report?
Top Page
AstraZeneca
(LSE:AZN)
Select Model
Select Model
Rating:74Outperform
Price Target:
15,635.00 p
▲(25.32% Upside)
Action:Reiterated
Date:10/31/26
The score is driven primarily by strong underlying financial performance (high profitability, improving leverage) and a constructive earnings outlook with reaffirmed guidance and significant pipeline catalysts. Technicals support the uptrend but are somewhat extended (overbought signals), while valuation is a restraint given the higher P/E and modest dividend yield.
Positive Factors
Pipeline Depth
A deep late-stage pipeline supports durable growth beyond the current product base. Positive Phase III results, recent approvals, and substantial 2027 readouts can replenish launches, expand treated populations, and reduce reliance on any single medicine as older products mature.
Negative Factors
Loss of Exclusivity
Patent expiry and generic competition can create sustained revenue erosion in established medicines, as shown by the declines in Farxiga and broader CVRM. These pressures may continue to weigh on growth and require successful launches or indication expansion to offset lost sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline Depth
A deep late-stage pipeline supports durable growth beyond the current product base. Positive Phase III results, recent approvals, and substantial 2027 readouts can replenish launches, expand treated populations, and reduce reliance on any single medicine as older products mature.
Read all positive factors
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£216.51B
Dividend Yield1.71%
Average Volume (3M)2.70M
Price to Earnings (P/E)27.9
Beta (1Y)1.21
Revenue Growth4.71%
EPS Growth21.16%
CountryUK
Employees96,100
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)6.71
Shares Outstanding1,551,053,300
10 Day Avg. Volume2,561,433
30 Day Avg. Volume2,704,005
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)5.91
Price to Sales (P/S)4.90
P/FCF Ratio33.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£15,676.65Price Target Upside25.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)10.24
Revenue Forecast (FY)£62.87B
AstraZeneca Business Overview & Revenue Model
Company Description
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, ke...
How the Company Makes Money
AstraZeneca primarily makes money by selling patented, branded prescription medicines to wholesalers, pharmacies, hospitals, and government/healthcare systems across major regions (including the United States, Europe, and international markets). R...
AstraZeneca Earnings Call Summary
Earnings Call Date:Oct 30, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Feb 11, 2027
Earnings Call Sentiment Positive
The call was strongly positive overall. AstraZeneca reported solid revenue and EPS growth, broad-based commercial momentum, significant Phase III success, multiple new approvals and a deep pipeline with substantial 2027 catalysts. The company also reiterated full-year guidance and expressed confidence in growth through 2030 and beyond. Against this, the call included explicit challenges from loss of exclusivity, generic competition, VBP, lower operating cash flow, one clinical development discontinuation, higher investment and restructuring costs, and expected fourth-quarter expense pressures, but these were presented as manageable within the company's broader growth and pipeline strategy.Positive Updates
Strong Year-to-Date Revenue and EPS Growth
For the first 9 months of 2026, total revenue grew 7% and core EPS increased 14%. Excluding Farxiga and Brilinta, total revenue grew 12%, demonstrating the underlying strength of the broader portfolio.
Negative Updates
Biopharmaceuticals Revenue Declined 6%
Biopharmaceuticals total revenue declined 6% in the third quarter to $5.6 billion, as growth in respiratory and immunology was not sufficient to fully offset anticipated headwinds from Farxiga, Brilinta and roxadustat in CVRM.
Read all updates
Q3-2026 Updates
Positive
Negative
Strong Year-to-Date Revenue and EPS Growth
For the first 9 months of 2026, total revenue grew 7% and core EPS increased 14%. Excluding Farxiga and Brilinta, total revenue grew 12%, demonstrating the underlying strength of the broader portfolio.
Read all positive updates
Company Guidance
For the full year, AstraZeneca continues to expect total revenue to increase by a mid- to high single-digit percentage and core EPS to increase by low double-digit percentage; core gross margins are expected to be stable to slightly higher than in 2025, R&D is expected to be at the upper end of the low 20s percentage range, and the core tax rate is expected to be within 18% to 22%. Full year CapEx is now expected to increase by low teens percentage compared to 2025, milestone payments relating to prior BD transactions are expected to be approximately $2.5 billion, other operating income in the second half is expected to be slightly higher than the first half, and operating expenses are expected to show a sequential step-up in the fourth quarter versus third quarter, with finance expenses also expected to be higher in the fourth quarter than in the third quarter. The Reshaping for Sustainable Growth program is expected to incur up to $2 billion in onetime restructuring costs and deliver $1.5 billion in annualized pretax run rate benefits, with activities expected to be completed by the end of 2029; for 2027, the company expects more than 20 high-value trial readouts and pivotal data for 9 potential new medicines, representing more than $20 billion in non-risk-adjusted peak year revenue.AstraZeneca Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
74
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.27B | 58.74B | 52.94B | 46.58B | 44.25B | 37.11B |
| Gross Profit | 48.57B | 48.11B | 39.70B | 34.45B | 28.04B | 22.60B |
| EBITDA | 20.46B | 19.83B | 14.96B | 13.57B | 8.64B | 4.66B |
| Net Income | 10.43B | 10.22B | 6.89B | 6.06B | 3.28B | 109.85M |
Balance Sheet | ||||||
| Total Assets | 116.43B | 114.07B | 104.03B | 101.12B | 96.48B | 105.36B |
| Cash, Cash Equivalents and Short-Term Investments | 4.99B | 5.74B | 5.65B | 5.91B | 6.24B | 6.37B |
| Total Debt | 32.41B | 29.62B | 30.11B | 28.41B | 29.14B | 30.69B |
| Total Liabilities | 65.80B | 65.36B | 63.16B | 61.95B | 59.42B | 66.08B |
| Stockholders Equity | 50.56B | 48.67B | 40.79B | 39.14B | 37.04B | 39.27B |
Cash Flow | ||||||
| Free Cash Flow | 8.43B | 8.67B | 7.28B | 6.57B | 7.24B | 3.76B |
| Operating Cash Flow | 13.74B | 14.57B | 11.86B | 10.35B | 9.81B | 5.96B |
| Investing Cash Flow | -8.19B | -6.81B | -7.98B | -4.06B | -2.96B | -11.06B |
| Financing Cash Flow | -7.66B | -7.54B | -4.00B | -6.57B | -6.82B | 3.65B |
AstraZeneca Technical Analysis
Positive
12476.00
Price Trends
12307.28
Positive
12563.18
Positive
13342.67
Positive
Market Momentum
283.43
Negative
74.53
Negative
84.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AZN, the sentiment is Positive. The current price of 12476 is below the 20-day moving average (MA) of 12502.30, above the 50-day MA of 12307.28, and below the 200-day MA of 13342.67, indicating a bullish trend. The MACD of 283.43 indicates Negative momentum. The RSI at 74.53 is Negative, neither overbought nor oversold. The STOCH value of 84.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AZN.
AstraZeneca Risk Analysis
AstraZeneca disclosed 19 risk factors in its most recent earnings report. AstraZeneca reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment Q4, 2024
AstraZeneca Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £216.51B | 27.85 | 21.68% | 1.71% | 4.71% | 21.16% | |
70 Outperform | £4.67B | 51.61 | 8.40% | 2.28% | 1.94% | -43.71% | |
70 Outperform | £3.58B | 12.95 | 15.05% | 3.66% | 2.48% | 3.36% | |
69 Neutral | £74.37B | 17.18 | 24.64% | 3.67% | 4.28% | -19.93% | |
68 Neutral | £9.27B | 19.51 | 12.25% | 2.66% | 2.17% | 27.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GB:AZN
AstraZeneca
13,960.00
1,803.71
14.84%
GB:CTEC
ConvaTec
244.40
11.17
4.79%
GB:GSK
GlaxoSmithKline
1,855.00
158.39
9.34%
GB:HIK
Hikma Pharmaceuticals
1,731.00
-8.85
-0.51%
GB:SN
Smith & Nephew
1,107.50
-251.88
-18.53%
GB:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
54.00
12.92
31.44%
AstraZeneca Corporate Events
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Ultomiris Wins U.S. Accelerated Nod for IgA Nephropathy
Positive
Oct 22, 2026
AstraZeneca’s Alexion Rare Disease unit has secured U.S. accelerated approval for Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of disease progression, making it the first and only C5 com...
Business Operations and StrategyPrivate Placements and Financing
AstraZeneca invests $2bn in Summit to accelerate bispecific and ADC cancer portfolio
Positive
Oct 5, 2026
AstraZeneca has completed a $2 billion equity investment in Summit Therapeutics, strengthening its position in oncology and expanding access to novel immuno-oncology assets. The deal is designed to accelerate development of ivonescimab, a first-in...
Business Operations and StrategyPrivate Placements and Financing
AstraZeneca, Daiichi Sankyo and Summit expand ADC–immunotherapy push with Datroway–ivonescimab trials
Positive
Oct 2, 2026
AstraZeneca and Daiichi Sankyo have entered a new clinical collaboration with Summit Therapeutics to test the TROP2-directed antibody drug conjugate Datroway in combination with Summit’s bispecific immunotherapy ivonescimab across multiple t...
Business Operations and StrategyDelistings and Listing Changes
AstraZeneca Adds Employee Scheme Shares to London Listing
Neutral
Oct 1, 2026
AstraZeneca PLC has admitted 9,828 additional ordinary shares of $0.25 each to trading on the Main Market of the London Stock Exchange, bringing its total number of shares in issue to 1,551,053,289. These new shares are fully fungible with existin...
Regulatory Filings and Compliance
AstraZeneca Confirms Total Voting Rights and Share Capital Structure
Positive
Oct 1, 2026
AstraZeneca PLC has confirmed that as of 30 September 2026 its issued share capital with voting rights consists of 1,551,053,289 ordinary shares of US$0.25, with no shares held in treasury. This figure represents the total number of voting rights ...
Business Operations and StrategyPrivate Placements and Financing
AstraZeneca invests $2bn in Summit Therapeutics, deepening oncology ADC-bispecific ties
Positive
Sep 29, 2026
AstraZeneca has agreed to invest $2 billion in newly issued equity of Summit Therapeutics Inc., securing an economic stake of about 12% in the U.S. biotech to accelerate development of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody. T...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca wins EU nod for first triple-combination asthma inhaler
Positive
Sep 23, 2026
AstraZeneca has secured European Commission approval for Trixeo Aerosphere, the first triple-combination inhaler therapy authorised in the EU for maintenance treatment of asthma in patients aged 12 and over whose disease is inadequately controlled...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Alexion Wins Key EU Backing for Klygefa in Generalised Myasthenia Gravis
Positive
Sep 21, 2026
Alexion, AstraZeneca Rare Disease, has secured a positive opinion from the European Medicines Agency’s CHMP backing EU approval of Klygefa (gefurulimab) as an add-on therapy for adults with generalised myasthenia gravis who are anti-acetylch...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
AstraZeneca’s Enhertu Wins EU Backing to Redefine Adjuvant HER2-Positive Breast Cancer Care
Positive
Sep 21, 2026
AstraZeneca and Daiichi Sankyo have secured a positive opinion from the European Medicines Agency’s CHMP recommending Enhertu for approval as adjuvant monotherapy in adults with resected HER2-positive early breast cancer who have residual in...
Other
AstraZeneca CEO Pascal Soriot Buys 60,000 Company Shares
Positive
Sep 18, 2026
AstraZeneca disclosed that its chief executive officer, Pascal Soriot, purchased 60,000 ordinary shares of the company on 14 September 2026 at a price of £121.02 per share. The transaction, conducted on the London market and reported under UK...
Executive/Board ChangesRegulatory Filings and Compliance
AstraZeneca CFO Reports Vesting-Linked Share Acquisition Under 2021 Performance Plan
Positive
Sep 15, 2026
AstraZeneca has disclosed a small share acquisition by its Chief Financial Officer, Dr Aradhana Sarin, under the company’s performance-based remuneration framework. The transaction reflects the vesting of dividend-equivalent awards linked to...
Regulatory Filings and Compliance
AstraZeneca Chair Michel Demaré Buys Additional Shares in the Company
Positive
Sep 15, 2026
AstraZeneca PLC disclosed that its Non-Executive Chair of the Board, Michel Demaré, purchased 2,500 ordinary shares in the company on 14 September 2026. The transaction, executed in London at a price of about £121.21 per share, was notif...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Etcamah misses primary goal in key SERENA-4 breast cancer trial
Negative
Sep 14, 2026
AstraZeneca reported that its Phase III SERENA-4 trial of Etcamah (camizestrant) combined with CDK4/6 inhibitor palbociclib in first-line treatment of ER-positive, HER2-negative advanced breast cancer failed to achieve a statistically significant ...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca Wins U.S. Approval for Etcamah Combo to Tackle Endocrine‑Resistant Breast Cancer
Positive
Sep 7, 2026
AstraZeneca has secured U.S. accelerated approval for its oral selective estrogen receptor degrader Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adults with HR‑positive, HER2‑negative, locally advanced or metastati...
Business Operations and StrategyDelistings and Listing Changes
AstraZeneca Adds Employee Scheme Shares to London Listing
Neutral
Sep 1, 2026
AstraZeneca has admitted 10,072 additional ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market, bringing its total shares in issue to 1,551,043,461. These new shares are fully fungible with existing stock and ...
Regulatory Filings and Compliance
AstraZeneca Confirms Total Voting Rights Following Share Capital Update
Neutral
Sep 1, 2026
AstraZeneca has confirmed that as of 31 August 2026 its issued share capital with voting rights stands at 1,551,043,461 ordinary shares, with no shares held in treasury, resulting in an equal number of total voting rights. This figure serves as th...
Business Operations and StrategyPrivate Placements and Financing
AstraZeneca Taps Euro Debt Markets With €2.55 Billion Multi-Tranche Bond
Positive
Sep 1, 2026
AstraZeneca has raised €2.55 billion through its financing arm, AstraZeneca Finance LLC, with four euro-denominated note issues that have been admitted to trading on the London Stock Exchange’s Main Market. The tranches include notes m...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca and Daiichi Sankyo win EU nod for Enhertu combo in first-line HER2-positive metastatic breast cancer
Positive
Sep 1, 2026
AstraZeneca and Daiichi Sankyo have secured European Commission approval for Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer, marking ...
Executive/Board Changes
AstraZeneca strengthens board with appointment of Wan Ling Martello
Positive
Sep 1, 2026
AstraZeneca has appointed Wan Ling Martello as a Non-Executive Director, effective 1 September 2026, and she will join the company’s Audit Committee upon her board appointment. The move strengthens AstraZeneca’s governance with a direc...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca Secures Global Rights to Lung Cancer Drug Zegfrovy in $1.5 Billion Deal
Positive
Sep 1, 2026
AstraZeneca has completed its exclusive global licensing deal with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), securing worldwide rights to develop and commercialise the oral EGFR inhibitor for lung cancer. The drug is already approved in t...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Tagrisso–Orpathys combo delivers major first-line win in MET-overexpressing lung cancer
Positive
Sep 1, 2026
AstraZeneca and HUTCHMED reported that the SANOVO Phase III trial in China showed Tagrisso combined with Orpathys delivered a statistically significant and clinically meaningful progression-free survival benefit over Tagrisso alone in treatment-na...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Tezspire Hits Key Phase III Goals in Eosinophilic Esophagitis
Positive
Aug 27, 2026
AstraZeneca and Amgen reported that their biologic Tezspire delivered statistically significant and clinically meaningful improvements in eosinophilic esophagitis across all primary and key secondary endpoints in the Phase III CROSSING trial. Bene...
Business Operations and StrategyPrivate Placements and Financing
AstraZeneca Prices €2.55 Billion Eurobond to Support Long-Term Funding Strategy
Positive
Aug 25, 2026
AstraZeneca has tapped the euro debt markets through its finance subsidiary, pricing a €2.55 billion multi-tranche Eurobond offering that is fully and unconditionally guaranteed by the parent company. The notes, ranging in maturity from 2030...
Executive/Board ChangesRegulatory Filings and Compliance
AstraZeneca CFO Receives First Vesting Under Long-Term Performance Share Plan
Positive
Aug 19, 2026
AstraZeneca has reported the vesting of an award of ordinary shares to Chief Financial Officer Dr Aradhana Sarin under its Performance Share Plan. The award, originally granted in August 2021 and tied to scientific, commercial and financial metric...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Enhertu tops standard care in first-line HER2-mutant lung cancer trial
Positive
Aug 17, 2026
AstraZeneca and Daiichi Sankyo reported that their HER2-directed antibody-drug conjugate Enhertu significantly improved progression-free survival compared with the current global standard of care in a Phase III trial of first-line treatment for pa...
Business Operations and Strategy
AstraZeneca Halts Key Lung Cancer Trial of Volrustomig After Missed Efficacy Goals
Negative
Aug 17, 2026
AstraZeneca has halted its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy as a first-line treatment for metastatic non-small cell lung cancer patients whose tumours express PD-L1 below 50%, after an independent data monitor...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca’s Tagrisso–Orpathys Combo Delivers Phase III Survival Gains in MET-Driven Lung Cancer
Positive
Aug 17, 2026
AstraZeneca reported positive Phase III results from the global SAFFRON trial, showing that Tagrisso combined with Orpathys significantly improved progression-free and overall survival versus platinum-based chemotherapy in MET-driven EGFR-mutated ...
Business Operations and StrategyDelistings and Listing Changes
AstraZeneca Adds Employee Scheme Shares to London Listing
Neutral
Aug 3, 2026
AstraZeneca PLC has admitted 8,855 additional ordinary shares of $0.25 each to trading on the Main Market of the London Stock Exchange, bringing the total number of securities in issue to 1,551,033,389. These new shares are fully fungible with exi...
Regulatory Filings and Compliance
AstraZeneca Updates Market on Total Voting Rights
Neutral
Aug 3, 2026
AstraZeneca has reported that, as of 31 July 2026, its issued share capital with voting rights comprises 1,551,033,389 ordinary shares, with no shares held in treasury, resulting in an equal number of total voting rights. This updated voting right...
Business Operations and StrategyProduct-Related Announcements
AstraZeneca Wins EU Nod for Datroway, Strengthening TNBC Oncology Portfolio
Positive
Jul 31, 2026
AstraZeneca and Daiichi Sankyo have secured European Union approval for Datroway as the only TROP2-directed medicine with a demonstrated overall survival benefit in first-line treatment of unresectable or metastatic triple-negative breast cancer p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.